Ursolic acid inhibits early lesions of diabetic nephropathy

International Journal of Molecular Medicine

Volumn 26, Issue 4, 2010, Pages 565-570

  Zhou, Yi ^a   Li, Jian Shuang ^a   Zhang, Xin ^b   Wu, Ya Jun ^a   Huang, Kun ^b   Zheng, Ling ^a  

^a WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Diabetic nephropathy; MAPKs; STAT3; Uroslic acid

Indexed keywords

COLLAGEN TYPE 4; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; URSOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; KIDNEY CORTEX; KIDNEY HYPERTROPHY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

EID: 77957863271     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000500     Document Type: Article

References (39)

1. Schena FP and Gesualdo L: Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 16 (Suppl 1): 30-33, 2005.
2. Chen S, Jim B and Ziyadeh FN: Diabetic nephropathy and transforming growth factor-beta: Transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 23: 532-543, 2003. (Pubitemid 38030087)
3. Forbes JM, Coughlan MT and Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454, 2008.
4. Soldatos G and Cooper ME: Diabetic nephropathy: Important pathophysiologic mechanisms. Diabetes Res Clin Pract 82 (Suppl 1): 75-79, 2008.
5. Ma FY, Liu J and Nikolic-Paterson DJ: The role of stress-activated protein kinase signaling in renal pathophysiology. Braz J Med Biol Res 42: 29-37, 2009.
6. Lee CH, Wu SL, Chen JC, et al: Eriobotrya Japonica leaf and its triterpenes inhibited lipopolysaccharide-induced cytokines and inducible enzyme production via the nuclear factor-kappaB signaling pathway in lung epithelial cells. Am J Chin Med 36: 1185-1198, 2008.
7. Liu J: Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 49: 57-68, 1995.
8. Wang ZH, Hsu CC, Huang CN and Yin MC: Anti-glycative effects of oleanolic acid and ursolic acid in kidney of diabetic mice. Eur J Pharmacol 628: 255-260, 2009.
9. Zheng L, Szabo C and Kern TS: Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53: 2960-2967, 2004.
10. Zheng L, Du Y, Miller C, et al: Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 50: 1987-1996, 2007.
11. Zheng L, Gong B, Hatala DA and Kern TS: Retinal ischemia and reperfusion causes capillary degeneration: Similarities to diabetes. Invest Ophthalmol Vis Sci 48: 361-367, 2007.
12. Ota T, Takamura T, Ando H, Nohara E, Yamashita H and Kobayashi K: Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46: 843-851, 2003. (Pubitemid 36831414)
13. Lu TC, Wang ZH, Feng X, et al: Knockdown of STAT3 activity in vivo prevents diabetic glomerulopathy. Kidney Int 76: 63-71, 2009.
14. Wei P, Lane PH, Lane JT, Padanilam BJ and Sansom SC: Glomerular structural and functional changes in a high-fat diet mouse model of early-stage type 2 diabetes. Diabetologia 47: 1541-1549, 2004.
15. Inagi R, Yamamoto Y, Nangaku M, et al: A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 55: 356-366, 2006.
16. Qian Y, Feldman E, Pennathur S, Kretzler M and Brosius FC III: From fibrosis to sclerosis: Mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 57: 1439-1445, 2008.
17. Furness PN: Extracellular matrix and the kidney. J Clin Pathol 49: 355-359, 1996.
18. Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9: 798-809, 2009.
19. Wegrzyn J, Potla R, Chwae YJ, et al: Function of mitochondrial STAT3 in cellular respiration. Science 323: 793-797, 2009.
20. Adhikary L, Chow F, Nikolic-Paterson DJ, et al: Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 47: 1210-1222, 2004. (Pubitemid 39093317)
21. Pathak AK, Bhutani M, Nair AS, et al: Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res 5: 943-955, 2007.
22. Wang X, Shaw S, Amiri F, Eaton DC and Marrero MB: Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in TGF-beta and fibronectin synthesis in mesangial cells. Diabetes 51: 3505-3509, 2002.
23. Shi Y, Zhang Y, Wang C, et al: Suppressor of cytokine signaling-1 reduces high glucose-induced tgf-beta1 and fibronectin synthesis in human mesangial cells. FEBS Lett 582: 3484-3488, 2008.
24. Berthier CC, Zhang H, Schin M, et al: Enhanced expression of janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58: 469-477, 2009.
25. Banes AK, Shaw S, Jenkins J, et al: Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 286: F653-F659, 2004.
26. Rivero A, Mora C, Muros M, Garcia J, Herrera H and Navarro-Gonzalez JF: Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci 116: 479-492, 2009.
27. Zheng L, Howell SJ, Hatala DA, Huang K and Kern TS: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 56: 337-345, 2007. (Pubitemid 46263071)
28. Vareniuk I, Pavlov IA and Obrosova IG: Inducible nitric oxide synthase gene deficiency counteracts multiple manifestations of peripheral neuropathy in a streptozotocin-induced mouse model of diabetes. Diabetologia 51: 2126-2133, 2008.
29. Zheng L and Kern TS: Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front Biosci 14: 3974-3987, 2009.
30. Fan Q, Liao J, Kobayashi M, et al: Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 19: 3012-3020, 2004.
31. Okada S, Saito M, Kazuyama E, et al: Effects of N-hexacosanol on nitric oxide synthase system in diabetic rat nephropathy. Mol Cell Biochem 315: 169-177, 2008.
32. Trachtman H, Futterweit S, Pine E, Mann J and Valderrama E: Chronic diabetic nephropathy: Role of inducible nitric oxide synthase. Pediatr Nephrol 17: 20-29, 2002. (Pubitemid 41490200)
33. Marrero MB, Fulton D, Stepp D and Stern DM: Angiotensin II-induced signaling pathways in diabetes. Curr Diabetes Rev 1: 197-202, 2005.
34. Lim AK, Nikolic-Paterson DJ, Ma FY, et al: Role of MKK3-p38 MAPK signalling in the development of type 2 diabetes and renal injury in obese db/db mice. Diabetologia 52: 347-358, 2009.
35. Al-Rasheed NM, Meakin F, Royal EL, et al: Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells. Diabetologia 47: 987-997, 2004.
36. Lin CL, Wang FS, Kuo YR, et al: Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int 69: 1593-1600, 2006.
37. Toyoda M, Suzuki D, Honma M, et al: High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int 66: 1107-1114, 2004. (Pubitemid 39121016)
38. Ma FY, Flanc RS, Tesch GH, et al: A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc Nephrol 18: 472-484, 2007.
39. Goruppi S, Bonventre JV and Kyriakis JM: Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 21: 5427-5436, 2002.